Table 4.
N* | Prescribing | N* | Review | N* | TAU | p Value (between groups† | |
---|---|---|---|---|---|---|---|
Baseline HADS-D | 44 | Count (%) | 45 | Count (%) | 53 | Count (%) | |
Normal | 32 (72.7) | 31 (68.9) | 38 (71.7) | ||||
Mild | 8 (18.2) | 11 (24.4) | 7 (13.2) | ||||
Moderate | 3 (6.8) | 3 (6.7) | 8 (15.1) | ||||
Severe | 1 (2.3) | 0 | 0 | ||||
6-month follow-up HADS-D | |||||||
Normal | 32 (72.7) | 32 (71.1) | 32 (60.4) | ||||
Mild | 7 (15.9) | 6 (13.3) | 10 (18.9) | ||||
Moderate | 5 (11.4) | 6 (13.3) | 8 (15.1) | ||||
Severe | 0 | 1 (2.2) | 3 (5.7) | ||||
Difference HADS-D | |||||||
≤–1 | 5 (11.4) | 4 (8.9) | 2 (3.8) | ||||
0 | 34 (77.3) | 37 (82.0) | 40 (75.5) | ||||
≥1 | 5 (11.4) | 4 (8.9) | 11 (20.8) | 0.32 | |||
p (within groups‡) | 1.0 | 0.71 | 0.03 | ||||
Baseline HADS-A | 44 | Count (%) | 43 | Count (%) | 48 | Count (%) | |
Normal | 25 (56.8) | 30 (69.8) | 29 (60.4) | ||||
Mild | 8 (18.2) | 7 (16.3) | 9 (18.8) | ||||
Moderate | 8 (18.2) | 5 (11.6) | 8 (16.7) | ||||
Severe | 3 (6.8) | 1 (2.3) | 2 (4.2) | ||||
6-month follow-up HADS-A | |||||||
Normal | 27 (61.4) | 29 (67.4) | 32 (66.7) | ||||
Mild | 7 (15.9) | 6 (14.0) | 5 (10.4) | ||||
Moderate | 8 (18.2) | 6 (14.0) | 10 (20.8) | ||||
Severe | 2 (4.5) | 2 (4.7) | 1 (2.1) | ||||
Difference HADS-A | |||||||
≤–1 | 6 (13.6) | 3 (7.0) | 10 (20.8) | ||||
0 | 35 (79.5) | 33 (76.7) | 29 (60.4) | ||||
≥1 | 3 (6.8) | 7 (16.3) | 9 (18.8) | 0.14 | |||
p (within groups‡) | 0.25 | 0.21 | 0.55 |
Within-arm and between-arm p values are also reported.
*Number of participants in each group who completed the appropriate part of the HADS at both baseline and follow-up.
†From χ² test on difference in HADS.
‡From marginal homogeneity test.